RDG Stock Overview
Engages in the detection, prevention, and treatment of various types of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Read-Gene S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł4.67 |
| 52 Week High | zł7.80 |
| 52 Week Low | zł3.36 |
| Beta | -1.09 |
| 11 Month Change | -5.66% |
| 3 Month Change | -21.64% |
| 1 Year Change | 33.43% |
| 33 Year Change | 71.69% |
| 5 Year Change | 531.08% |
| Change since IPO | 72.96% |
Recent News & Updates
Does Read-Gene (WSE:RDG) Have A Healthy Balance Sheet?
Jul 17
Read-Gene (WSE:RDG) Is Making Moderate Use Of Debt
Feb 14
Shareholder Returns
| RDG | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -10.9% | -3.5% | -0.2% |
| 1Y | 33.4% | -18.1% | 0.3% |
Return vs Industry: RDG exceeded the Polish Biotechs industry which returned -18.1% over the past year.
Return vs Market: RDG exceeded the Polish Market which returned 0.3% over the past year.
Price Volatility
| RDG volatility | |
|---|---|
| RDG Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.4% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: RDG's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: RDG's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 22 | Jan Lubinski | www.read-gene.com |
Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. Chemoprevention is the use of natural or synthetic substances to stop, reverse, or delay the process of developing cancer.
Read-Gene S.A. Fundamentals Summary
| RDG fundamental statistics | |
|---|---|
| Market cap | zł55.06m |
| Earnings (TTM) | -zł1.00m |
| Revenue (TTM) | zł11.63m |
4.7x
P/S Ratio-54.9x
P/E RatioIs RDG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDG income statement (TTM) | |
|---|---|
| Revenue | zł11.63m |
| Cost of Revenue | zł852.51k |
| Gross Profit | zł10.78m |
| Other Expenses | zł11.78m |
| Earnings | -zł1.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.085 |
| Gross Margin | 92.67% |
| Net Profit Margin | -8.63% |
| Debt/Equity Ratio | 223.8% |
How did RDG perform over the long term?
See historical performance and comparison